Departamento de Cirurgia e Fisiologia, Faculdade de Medicina da Universidade do Porto, 4200-319 Porto, Portugal.
Departamento de Angiologia e Cirurgia Vascular, Hospital CUF Porto, 4100-180 Porto, Portugal.
Int J Mol Sci. 2018 Jun 5;19(6):1669. doi: 10.3390/ijms19061669.
Chronic venous disease (CVD) is a common pathology, with significant physical and psychological impacts for patients and high economic costs for national healthcare systems. Throughout the last decades, several risk factors for this condition have been identified, but only recently, have the roles of inflammation and endothelial dysfunction been properly assessed. Although still incompletely understood, current knowledge of the pathophysiological mechanisms of CVD reveals several potential targets and strategies for therapeutic intervention, some of which are addressable by currently available venoactive drugs. The roles of these drugs in the clinical improvement of venous tone and contractility, reduction of edema and inflammation, as well as in improved microcirculation and venous ulcer healing have been studied extensively, with favorable results reported in the literature. Here, we aim to review these pathophysiological mechanisms and their implications regarding currently available venoactive drug therapies.
慢性静脉疾病（CVD）是一种常见的病理，对患者的身体和心理都有重大影响，也给国家医疗保健系统带来了巨大的经济负担。在过去的几十年中，已经确定了这种疾病的多种危险因素，但直到最近，炎症和内皮功能障碍的作用才得到适当评估。尽管目前对 CVD 的病理生理机制仍不完全了解，但现有的知识揭示了一些潜在的治疗干预靶点和策略，其中一些可以通过目前可用的静脉活性药物来解决。这些药物在改善静脉张力和收缩性、减轻水肿和炎症、改善微循环以及促进静脉溃疡愈合方面的作用已经得到了广泛的研究，文献中报告了良好的结果。在这里，我们旨在回顾这些病理生理机制及其对目前可用的静脉活性药物治疗的影响。
